First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Authors: Yung‐Jue Bang, Giuseppe Giaccone, S.-A. Im, Do‐Youn Oh, Todd M. Bauer, Jeffrey L. Nordstrom, H. Li, Gurunadh R. Chichili, Paul A. Moore, Soo-Hwa Hong, Samantha Stewart, Jan Baughman, Robert J. Lechleider, Howard A. Burris - Annals of Oncology 2017 cited by 225